CN101112398A - Application of typhoid fever and paratyphoid fever salmonella in the aspect of fast anti-tumor - Google Patents
Application of typhoid fever and paratyphoid fever salmonella in the aspect of fast anti-tumor Download PDFInfo
- Publication number
- CN101112398A CN101112398A CNA2007101455061A CN200710145506A CN101112398A CN 101112398 A CN101112398 A CN 101112398A CN A2007101455061 A CNA2007101455061 A CN A2007101455061A CN 200710145506 A CN200710145506 A CN 200710145506A CN 101112398 A CN101112398 A CN 101112398A
- Authority
- CN
- China
- Prior art keywords
- tumor
- group
- time
- application
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention discloses an application of typhoid and paratyphoid salmonella in the anti-tumor aspect, which is invented to solve the problems of great side effects and poor effects of the prior art in the treatment of tumors. The present invention provides the application of the typhoid and paratyphoid salmonella in the rapid anti-tumor aspect. Wherein, the tumors are one or more of gastric cancer, lung cancer, liver cancer, tongue squamous cancer, breast cancer, colon cancer, leukemia, brain tumor and sarcoma. The invention makes use of the rapid combination of the typhoid and paratyphoid salmonella with the mononuclear cells after entering into the human body, the strong endotoxin and bacteremia are released and the temperature reaches highly around 40 DEG C to 42 DEG C, so as to affect and inhibit the growth and the life cycle of the tumor cells, furthermore, the large mononuclear cells-macrophages in the reticuloendothelial system are proliferated greatly, thus enhancing the ability of the macrophages in vivo to swallow the cancer cells, so the invention has very significant inhibiting and killing effects of a variety of tumors.
Description
Technical field
The present invention relates to the application of typhoid fever, bacillus paratyphosus fast anti-tumor aspect.
Background technology
Malignant tumor (cancer) is a class serious threat human life and healthy disease.According to up-to-date statistics, the annual New Development cancer patient about about 1,600,000 of China, dead about 1,300,000, seize about 6,000,000 people's life every year in global cancer, and 1,000 ten thousand people are placed dead edge, along with going from bad to worse of environment for human survival, the incidence rate of tumor is ascendant trend year by year.World Health Organization's prediction 21 century cancer will become human dead " first killer ".Modern medicine mainly is that the operative treatment cooperation is put, chemotherapy to tumor treatment at present.Though operation can be removed primary lesion, but can not fundamentally stop the regeneration and the breeding of tumor cell, and this root of tumor recurrence and transfer in the future just, though put, chemotherapy can kill cancerous cell, but also make a large amount of normal tissue cells be subjected to grievous injury simultaneously, bring out gastrointestinal reaction, bone marrow depression and Liver and kidney, impairment of cardiac function, make the various internal organs of health seriously depleted, be difficult to accept further treatment, finally cause patient death.
We select and utilize typhoid fever, bacillus paratyphosus to the powerful inhibition of cancerous cell pointedly for this reason
Typhoid fever is to be by paratyphoid fever, second, the third three kinds of acute infectiouss disease of the digestive tract of whole body that Salmonella causes through alimentary infection by Salmonella typhi, paratyphoid fever.In the early days of foundation, because people's sanitary condition is relatively poor, its M ﹠ M is higher, once once caused serious injury to people, but along with progress of science and technology and antibiotic use, the mortality rate of typhoid fever is approximately (comprising infant and old people, in addition, between twenty and fifty mortality rate will reduce greatly) between the 0.5-1% now.Its pathogeny is: Salmonella typhi is invaded intestinal mucosa after entering small intestinal with water that pollutes or food, and the part pathogenic bacteria breeds by macrophage phagocytic and in its endochylema; Part enters the ileum aggregated lymphatic follicles through lymphatic vessel, breeds in solitary lymphatic follicles and the mesenteric lymph node, enters blood flow by thoracic duct then and causes of short duration bacteremia.This stage is equivalent to incubation period clinically.Salmonella typhi enters liver, spleen and other reticuloendothelial systems with blood flow and continues a large amount of breedings, enters blood flow once more, causes for the second time serious bacteremia, and discharges intensive endotoxin, causes clinical onset.The main pathological characteristic of typhoid fever is the hypertrophy of large mononuclear cell-macrophage in the whole body reticuloendothelial system, and its phagocyte ability is very active.
Summary of the invention
For overcoming above-mentioned defective, the object of the invention is to provide the application at anti-tumor aspect of a kind of typhoid fever, bacillus paratyphosus
For achieving the above object, the present invention proposes the application of typhoid fever, bacillus paratyphosus fast anti-tumor aspect.Wherein, above-mentioned tumor is a kind of in gastric cancer, hepatocarcinoma, pulmonary carcinoma, breast carcinoma, tongue squamous cell carcinoma, colon cancer, leukemia, the cerebral tumor and the sarcoma.
After utilizing typhoid fever, bacillus paratyphosus in entering human body, can promptly combine with mononuclear cell, and discharge high temperature about intensive endotoxin, bacteremia and 40-42 ℃, growth and life cycle with influence and containment tumor cell, and make the hypertrophy in large quantities of large mononuclear cell-macrophage in the whole body reticuloendothelial system, strengthen the ability of engulfing cancerous cell of macrophage in the body, therefore various tumors have been had containment and killing action very significantly.
The specific embodiment
The present invention proposes the application of typhoid fever, bacillus paratyphosus fast anti-tumor aspect, below with comparatively representative severally be further described as experimental example in the tumor.
Test the application of 1 Salmonella typhi in anti-hepatocarcinoma
Experiment material: injection Salmonella typhi: typhoid fever (50071)
Experimental technique: select 32 kunming mouses, female, 20g ± 2, inoculation H22, hepatoma carcinoma cell 1 * 10
6/ only, the right side axillary fossa is subcutaneous.Be divided into 4 groups next day at random: matched group, low dose group (1250U/ only/time), middle dosage group (2500U/ only/time) and high dose group (5000U/ only/time), 8 every group, calculate the existence natural law of every group of mice.
Experimental result:
| Sequence number | Group | Mean survival time (MST) |
| 1 | Matched group | 15 ± 3 days |
| 2 | Low dose group (1250U//time) | 22 ± 5 days |
| 3 | Middle dosage group (2500U//time) | 27 ± 5 days |
| 4 | High dose group (5000U//time) | 28 ± 3 days |
From The above results, Salmonella typhi typhoid fever (50071) has fairly obvious therapeutical effect to mice H22 hepatocarcinoma.
Test the application of 2 Salmonella typhis in anti-pulmonary carcinoma
Experiment material: injection Salmonella typhi: typhoid fever (50071)
Experimental technique: select 40 C57/bl mices, male, 20g ± 2, inoculation lewis, lung carcinoma cell 2 * 10
6/ only, the right side axillary fossa is subcutaneous.Be divided into 4 groups next day at random: matched group, low dose group (1250U/ only/time), middle dosage group (2500U/ only/time) and high dose group (5000U/ only/time), 10 every group, calculate the existence natural law of every group of mice.
Experimental result:
| Sequence number | Group | Mean survival time (MST) |
| 1 | Matched group | 20 ± 4 days |
| 2 | Low dose group (1250U//time) | 21 ± 5 days |
| 3 | Middle dosage group (2500U//time) | 25 ± 5 days |
| 4 | High dose group (5000U//time) | 30 ± 6 days |
From The above results, Salmonella typhi has fairly obvious therapeutical effect to mice lewis pulmonary carcinoma.
Test the application of 3 bacillus paratyphosuses in anti-breast cancer
Experiment material: bacillus paratyphosus: paratyphoid A (50001)
Experimental technique: select 40 Balb/c mices, female, 20g ± 2, inoculation EMT-6, breast cancer cell 5 * 10
6/ only, the right side axillary fossa is subcutaneous.Be divided into 4 groups next day at random: matched group, low dose group (1250U/ only/time), middle dosage group (2500U/ only/time) and high dose group (5000U/ only/time), 10 every group, calculate the existence natural law of every group of mice.
Experimental result:
| Sequence number | Group | Mean survival time (MST) |
| 1 | Matched group | 18 ± 5 days |
| 2 | Low dose group (1250U//time) | 20 ± 4 days |
| 3 | Middle dosage group (2500U//time) | 22 ± 6 days |
| 4 | High dose group (5000U//time) | 30 ± 5 days |
From The above results, paratyphoid A (50001) has fairly obvious therapeutical effect to mice EMT-6 breast carcinoma.
Test the application of 4 bacillus paratyphosuses in leukemia
Experiment material: bacillus paratyphosus: paratyphoid A (50001)
Select 20 615 inbred mouses, female, 20g ± 2, inoculation L-615, the leukaemia 5 * 10
6/ only, the right side axillary fossa is subcutaneous.Be divided into 4 groups next day at random: matched group, low dose group (1250U/ only/time), middle dosage group (2500U/ only/time) and high dose group (5000U/ only/time), 5 every group, calculate the existence natural law of every group of mice.
Experimental result:
| Sequence number | Group | Mean survival time (MST) |
| 1 | Matched group | 8 ± 4 days |
| 2 | Low dose group (1250U//time) | 10 ± 4 days |
| 3 | Middle dosage group (2500U//time) | 15 ± 6 days |
| 4 | High dose group (5000U//time) | 19 ± 7 days |
From The above results, paratyphoid A (50001) has fairly obvious therapeutical effect to mice L-615 leukemia.
Test the application of 5 bacillus paratyphosuses in resistive connection intestinal cancer
Experiment material: bacillus paratyphosus: paratyphoid B (50094)
Experimental technique: select 20 C57/bl inbred mouses, female, 20g ± 2, inoculation Z-38, colon cancer cell 5 * 10
6/ only, the right side axillary fossa is subcutaneous.Be divided into 4 groups next day at random: matched group, low dose group (1250U/ only/time), middle dosage group (2500U/ only/time) and high dose group (5000U/ only/time), 5 every group, calculate the existence natural law of every group of mice.
Experimental result:
| Sequence number | Group | Mean survival time (MST) |
| 1 | Matched group | 30 ± 5 days |
| 2 | Low dose group (1250U//time) | 35 ± 4 days |
| 3 | Middle dosage group (2500U//time) | 39 ± 5 days |
| 4 | High dose group (5000U//time) | 44 ± 7 days |
From The above results, paratyphoid B (50094) has fairly obvious therapeutical effect to mice Z-38 colon cancer.
Test the application of 6 bacillus paratyphosuses in anti-gastric cancer
Experiment material: bacillus paratyphosus: paratyphoid B (50094)
Experimental technique: select 28 BALB/C-NU nude mices, female, 20g ± 2, inoculation BGC803, stomach cancer cell 2 * 10
6/ only, the right side axillary fossa is subcutaneous.Be divided into 4 groups next day at random: matched group, low dose group (1250U/ only/time), middle dosage group (2500U/ only/time) and high dose group (5000U/ only/time), 7 every group, calculate the existence natural law of every group of mice.
Experimental result:
| Sequence number | Group | Mean survival time (MST) |
| 1 | Matched group | 30 ± 5 days |
| 2 | Low dose group (1250U//time) | 36 ± 4 days |
| 3 | Middle dosage group (2500U//time) | 40 ± 5 days |
| 4 | High dose group (5000U//time) | 45 ± 7 days |
From The above results, paratyphoid B (50094) has fairly obvious therapeutical effect to mice BGC803 gastric cancer.
Test the application of 7 bacillus paratyphosuses in resistive connection intestinal cancer
Experiment material: bacillus paratyphosus: paratyphoid B (50004)
Experimental technique: select 20 BALB/C-NU nude mices, female, 20g ± 2, inoculation HCT-8, colon cancer cell 2 * 10
6/ only, the right side axillary fossa is subcutaneous.Be divided into 4 groups next day at random: matched group, low dose group (1250U/ only/time), middle dosage group (2500U/ only/time) and high dose group (5000U/ only/time), 5 every group, calculate the existence natural law of every group of mice.
Experimental result:
| Sequence number | Group | Mean survival time (MST) |
| 1 | Matched group | 25 ± 6 days |
| 2 | Low dose group (1250U//time) | 29 ± 5 days |
| 3 | Middle dosage group (2500U//time) | 35 ± 4 days |
| 4 | High dose group (5000U//time) | 39 ± 6 days |
From The above results, paratyphoid B (50004) has fairly obvious therapeutical effect to mice HCT-8 colon cancer.
Test the application of 8 bacillus paratyphosuses in anti-tongue squamous cell carcinoma
Experiment material: bacillus paratyphosus: paratyphoid B (50004)
Experimental technique: select 20 BALB/C-NU nude mices, female, 20g ± 2, inoculation TAC, tongue squamous cell carcinoma cell 2 * 10
6/ only, the right side axillary fossa is subcutaneous.Be divided into 4 groups next day at random: matched group, low dose group (1250U/ only/time), middle dosage group (2500U/ only/time) and high dose group (5000U/ only/time), 5 every group, calculate the existence natural law of every group of mice.
Experimental result:
| Sequence number | Group | Mean survival time (MST) |
| 1 | Matched group | 35 ± 6 days |
| 2 | Low dose group (1250U//time) | 40 ± 5 days |
| 3 | Middle dosage group (2500U//time) | 44 ± 4 days |
| 4 | High dose group (5000U//time) | 46 ± 6 days |
From The above results, paratyphoid B (50004) has fairly obvious therapeutical effect to mice TAC tongue squamous cell carcinoma.
Test the application of 9 bacillus paratyphosuses in anti-tongue squamous cell carcinoma
Experiment material: bacillus paratyphosus: paratyphoid A (50443)
Experimental technique: select 32 outbreeding system kunming mices, female, 20g ± 2, inoculation TAC, cerebroma cell 5 * 10
6/ only, the right side axillary fossa is subcutaneous.Be divided into 4 groups next day at random: matched group, low dose group (1250U/ only/time), middle dosage group (2500U/ only/time) and high dose group (5000U/ only/time), 8 every group, calculate the existence natural law of every group of mice.
Experimental result:
| Sequence number | Group | Mean survival time (MST) |
| 1 | Matched group | 16 ± 4 days |
| 2 | Low dose group (1250U//time) | 19 ± 6 days |
| 3 | Middle dosage group (2500U//time) | 25 ± 4 days |
| 4 | High dose group (5000U//time) | 32 ± 6 days |
From The above results, paratyphoid A (50443) has fairly obvious therapeutical effect to mice TAC cerebroma cell.
Test the application of 10 bacillus paratyphosuses in anti-sarcoma
Experiment material: bacillus paratyphosus: paratyphoid A (50443)
Experimental technique: select 20 outbreeding system kunming mices, female, 20g ± 2, inoculation S180, sarcoma cell 5 * 10
6/ only, the right side axillary fossa is subcutaneous.Be divided into 4 groups next day at random: matched group, low dose group (1250U/ only/time), middle dosage group (2500U/ only/time) and high dose group (5000U/ only/time), 5 every group, calculate the existence natural law of every group of mice.
Experimental result:
| Sequence number | Group | Mean survival time (MST) |
| 1 | Matched group | 10 ± 2 days |
| 2 | Low dose group (1250U//time) | 15 ± 5 days |
| 3 | Middle dosage group (2500U//time) | 19 ± 6 days |
| 4 | High dose group (5000U//time) | 28 ± 5 days |
From The above results, paratyphoid A (50443) has fairly obvious therapeutical effect to mice S180 sarcoma.
To sum up, can know that typhoid fever, bacillus paratyphosus (comprising typhoid fever behind the attenuation, bacillus paratyphosus) have direct and indirect killing action to tumor as those of ordinary skill in the art.
Above-mentioned Salmonella typhi typhoid fever (50071), paratyphoid A (50001), paratyphoid A (50443), paratyphoid B (50094), paratyphoid B (50004) are identified institute available from Beijing biological product.
Claims (10)
1. the application of typhoid fever, bacillus paratyphosus fast anti-tumor aspect.
2. the application of typhoid fever as claimed in claim 1, bacillus paratyphosus fast anti-tumor aspect is characterized in that: described tumor is a gastric cancer.
3. the application of typhoid fever as claimed in claim 1, bacillus paratyphosus fast anti-tumor aspect is characterized in that: described tumor is a pulmonary carcinoma.
4. the application of typhoid fever as claimed in claim 1, bacillus paratyphosus fast anti-tumor aspect is characterized in that: described tumor is a breast carcinoma.
5. the application of typhoid fever as claimed in claim 1, bacillus paratyphosus fast anti-tumor aspect is characterized in that: described tumor is a colon cancer.
6. the application of typhoid fever as claimed in claim 1, bacillus paratyphosus fast anti-tumor aspect is characterized in that: described tumor is the cerebral tumor.
7. the application of typhoid fever as claimed in claim 1, bacillus paratyphosus fast anti-tumor aspect is characterized in that: described tumor is a sarcoma.
8. the application of typhoid fever as claimed in claim 1, bacillus paratyphosus fast anti-tumor aspect is characterized in that: described tumor is a leukemia.
9. the application of typhoid fever as claimed in claim 1, bacillus paratyphosus fast anti-tumor aspect is characterized in that: described tumor is a hepatocarcinoma.
10. the application of typhoid fever as claimed in claim 1, bacillus paratyphosus fast anti-tumor aspect is characterized in that: described tumor is the tongue squamous cell carcinoma.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007101455061A CN101112398A (en) | 2007-08-28 | 2007-08-28 | Application of typhoid fever and paratyphoid fever salmonella in the aspect of fast anti-tumor |
| PCT/CN2008/001513 WO2009030103A1 (en) | 2007-08-28 | 2008-08-22 | The uses of salmonella typhi or salmonella paratyphi for preparation of medicaments for combating tumors |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007101455061A CN101112398A (en) | 2007-08-28 | 2007-08-28 | Application of typhoid fever and paratyphoid fever salmonella in the aspect of fast anti-tumor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101112398A true CN101112398A (en) | 2008-01-30 |
Family
ID=39021026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007101455061A Pending CN101112398A (en) | 2007-08-28 | 2007-08-28 | Application of typhoid fever and paratyphoid fever salmonella in the aspect of fast anti-tumor |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN101112398A (en) |
| WO (1) | WO2009030103A1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009030103A1 (en) * | 2007-08-28 | 2009-03-12 | Shucang Luo | The uses of salmonella typhi or salmonella paratyphi for preparation of medicaments for combating tumors |
| CN101485654B (en) * | 2009-03-03 | 2010-12-08 | 山东大学 | Application of T-2 toxin in preparing medicament for treating solid tumor |
| CN101984964B (en) * | 2009-03-03 | 2012-03-07 | 山东大学 | Application of T-2 toxin to preparing drugs for treating renal cell carcinomas |
| CN101669973B (en) * | 2008-09-12 | 2013-06-19 | 马逸冰 | Biological immunopotentiator composition for treating cancers |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6190657B1 (en) * | 1995-06-07 | 2001-02-20 | Yale University | Vectors for the diagnosis and treatment of solid tumors including melanoma |
| US20050180985A9 (en) * | 2001-10-04 | 2005-08-18 | Vladoianu Ion R. | Live attenuated salmonella strains for producing monovalent or multivalent vaccines |
| CN101112398A (en) * | 2007-08-28 | 2008-01-30 | 罗舒仓 | Application of typhoid fever and paratyphoid fever salmonella in the aspect of fast anti-tumor |
-
2007
- 2007-08-28 CN CNA2007101455061A patent/CN101112398A/en active Pending
-
2008
- 2008-08-22 WO PCT/CN2008/001513 patent/WO2009030103A1/en active Application Filing
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009030103A1 (en) * | 2007-08-28 | 2009-03-12 | Shucang Luo | The uses of salmonella typhi or salmonella paratyphi for preparation of medicaments for combating tumors |
| CN101669973B (en) * | 2008-09-12 | 2013-06-19 | 马逸冰 | Biological immunopotentiator composition for treating cancers |
| CN101485654B (en) * | 2009-03-03 | 2010-12-08 | 山东大学 | Application of T-2 toxin in preparing medicament for treating solid tumor |
| CN101984964B (en) * | 2009-03-03 | 2012-03-07 | 山东大学 | Application of T-2 toxin to preparing drugs for treating renal cell carcinomas |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009030103A1 (en) | 2009-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101544686A (en) | Application of glycopeptide mixture in preparing adjuvant therapy medicaments of tumor and health food | |
| EP0500739A1 (en) | Herbal treatment of malignancy. | |
| CN101112398A (en) | Application of typhoid fever and paratyphoid fever salmonella in the aspect of fast anti-tumor | |
| KR20220121176A (en) | Lacto-5X composition for improving intestinal function having improvement of intestinal adhesion and induction of microbiome change | |
| US9901602B2 (en) | Ejaculum of animals as medicinal material and uses thereof in medicaments for treatment of diseases such as tumors, depression, etc | |
| CN101152165A (en) | Antineoplastic isoliquirtigenin tablet | |
| CN105596994A (en) | Medicine for treating lung cancer cell proliferation | |
| Manchanda et al. | Scleredema associated with carcinoma of the gall bladder | |
| WO2018171672A1 (en) | Anti-cancer pharmaceutical composition and use thereof | |
| CN105688147A (en) | Traditional Chinese medicine composition for treating tumors | |
| CN111494385A (en) | Medicine for treating ovarian cancer and preparation method and application thereof | |
| CN104543714A (en) | Health instant potato porridge | |
| CN104352525A (en) | Freeze-dried goose blood powder for preventing and treating gastrointestinal tumors as well as preparation method and application thereof | |
| Heydari et al. | The effect of 8 weeks of quercetin supplementation and intermittent exercise on gene expression of Muc5Ac, Muc4 and polyphosphate in rats with colon cancer | |
| CN107519188B (en) | Gucosamine is preparing the application in radiotherapy hypersitization medicine | |
| CN114748579A (en) | Miao medicine for treating lung cancer and preparation method thereof | |
| Narayanasamy et al. | TH1. 6 Management of Phyllodes Tumour-a 10 years experience | |
| CN104398704A (en) | Traditional Chinese medicine composition for treating stomach cancer and preparation method thereof | |
| CN104473054A (en) | Instant rice porridge with tumor prevention and treatment functions | |
| RU2456009C1 (en) | Method of treating cystic fibrosis of breast in females of reproductive age | |
| CN109010586A (en) | It is a kind of for controlling the Chinese medicine composition and preparation method of tumour growth | |
| CN109453344A (en) | A kind of Chinese medicine composition for the treatment of cancer | |
| Sarker et al. | Metastatic male breast cancer | |
| CN103893628B (en) | A kind of pharmaceutical composition with food digesting action and preparation method thereof | |
| CN104489769A (en) | Snakehead fish ball food |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20080130 |